a16z Launches $1.1 Billion AI Hardware Fund, As Former Biotech Lead Shifts to Smaller, Open-Data Ventures

Featured image courtesy of a16z.

a16z, the venture capital firm, this week committed $1.1 billion to a new “Machine Age” fund, specifically designed to finance the physical infrastructure behind artificial intelligence. This move, reported by TechCrunch, marks a strategic expansion for a firm that has historically concentrated its investments on software companies. The capital infusion targets the hardware required to scale AI development and deployment, signaling a recognition that the next phase of AI growth depends as much on physical capacity as on algorithms.

The firm’s shift towards the physical buildout of AI infrastructure contrasts with the direction taken by one of its former partners. Vijay Pande, who departed a16z’s roughly $4 billion biotech practice last year, has since established VZVC, a fund operating with a much smaller scale. Pande’s new venture, as detailed in an interview with TechCrunch, centers on AI-native applications within biology, but with a distinct philosophy.

Pande describes biology as transitioning from a “discovery” science to an “engineering” discipline, a shift he believes AI can accelerate. He points to the persistent challenge of brutally expensive clinical trials as a key area where AI intervention can provide efficiencies. Crucially, VZVC’s investment approach emphasizes the importance of open, shared datasets. Pande argues that these open datasets, rather than proprietary or walled-off data silos, will be the true catalyst for AI’s transformative impact on medicine. This stance represents a departure from traditional biotech, where data often remains closely guarded.

The dual developments—a16z’s substantial commitment to AI hardware and Pande’s smaller, focused bets on AI-native biology with an open-data mandate—highlight diverging strategies across AI investment. On one side, a major venture firm is deploying over a billion dollars to address the foundational infrastructure needs of AI, acknowledging that software innovation alone cannot sustain the current pace of advancement. This suggests a belief that the bottlenecks for AI are increasingly physical, requiring large capital expenditure in chips, data centers, and specialized hardware.

On the other side, Pande’s VZVC illustrates a different thesis for AI application. His fund’s comparatively modest size and specific focus on AI in biology reflect a granular, application-centric view. Leaving a $4 billion practice to pursue “not doing 30 bets a year” with a smaller fund indicates a conviction that impactful AI development in specialized fields might benefit more from precise, targeted investments and a collaborative data environment, rather than the broad, high-volume approach often associated with larger funds. The emphasis on open datasets also suggests a challenge to the closed-loop data strategies that have characterized much of big tech and biotech development.

These two narratives, occurring almost simultaneously, paint a picture of how AI is being approached from different angles by investors. a16z, the institutional player, expands its thesis to capture value from the physical layer underpinning AI. Pande, the departed partner, takes a more specialized path, using AI to re-engineer an existing scientific discipline, prioritizing data access and efficiency over sheer scale of capital. Both acknowledge AI’s transformative power, but their strategies for realizing it through capital deployment and data philosophy offer contrasting models for the technology sector. The firm itself is moving to fund the physical infrastructure that makes AI possible, while a former leader is refining how AI is applied to a specific, complex domain, focusing on data sharing as a core principle.

How much capital did a16z allocate to its “Machine Age” fund?

a16z allocated $1.1 billion to its new “Machine Age” fund.

What is Vijay Pande’s new venture called?

Vijay Pande’s new venture is called VZVC.

What was the approximate size of a16z’s biotech practice before Pande left?

a16z’s biotech practice was approximately $4 billion before Vijay Pande left.

Compiled by Launch91 Desk from the sources linked above. More about Launch91.